Abstract Low-density lipoprotein receptors (LDLR) are appealing cell surface targets in drug delivery, as they are expressed in the blood-brain barrier (BBB) endothelium and are able to mediate transcytosis of functionalized drugs for molecular therapies of the central nervous system (CNS). On the other hand, braintargeted drug delivery is currently limited, among others, by the poor availability of biocompatible vehicles, as most of the nanoparticles under development as drug carriers pose severe toxicity issues. In this context, protein nanoparticles offer functional versatility, easy and cost-effective bioproduction, and full biocompatibility. In this study, we have designed and characterized several chimerical proteins containing different LDLR ligands, regarding their ability to bind and internalize target cells and to self-organize as viral mimetic nanoparticles of about 18 nm in diameter. While the self-assembling of LDLR-binding proteins as nanoparticles positively influences cell penetration in vitro, the nanoparticulate architecture might be not favoring BBB crossing in vivo. These findings are discussed in the context of the use of nanostructured materials as vehicles for the systemic treatment of CNS diseases.
specific cell types. A critical point in such design process is the selection of intrinsically non-toxic materials, which while keeping high structural and functional tunability would not induce side effects upon administration. Because of their biodegradability, biocompatibility, and functional and structural plasticity, proteins are highly convenient materials to construct carriers for the delivery of both conventional and emerging drugs (Lohcharoenkal et al. 2014) . On the other hand, drug vehicles, apart from exhibiting powerful targeting properties, should overcome the sequential biological barriers encountered previous to reaching the right cell compartment in the target organ. This is compulsory when targeting the central nervous system (CNS) that is protected by the blood-brain barrier (BBB) and by the blood spinal cord barrier (Peluffo et al. 2015) . Since in a therapeutic context, local administration into brain is not desirable because of its invasiveness (Lockman et al. 2002) , systemic administration is mandatory and empowering drugs to cross the BBB has become a major issue in current pharmacology and nanomedicine (Pardridge 2010) . BBB tightly controls the access of molecules and drugs to brain, either by paracellular or transcellular pathways, by using both functional and structural elements addressed to maintain brain homeostasis (Barbu et al. 2009 ). Hydrophilic and cationic small molecules show some spontaneous penetrability. However, usual chemical drugs and therapeutic proteins cannot cross the BBB or are targets for the efflux pumps acting in the BBB. A nanoparticulate organization of vehicles used for systemic drug delivery increases drug stability and circulation time (Céspedes et al. 2014) , what, by preventing renal filtration, offers potential for sustained release of the cargo. Although these and other properties of nanostructured materials are highly desirable, paracellular penetration of nanoparticles targeted to the CNS is assumed to be especially problematical. Functionalization with ligands of hormone receptors or transporters for transcytosis is then mandatory despite the unexpected BBB-crossing activities exhibited by a few polymers used for nanoparticle fabrication and coating [e.g., polysorbate 80 and poly-(ethylene glycol-co-hexadecyl)-cyanoacrylate (Kim et al. 2007; Kreuter et al. 2002)] .
A catalog of potential BBB-crossing peptides and proteins for functionalization is available (Van et al. 2012 ) (http://brainpeps.ugent.be). Among them, ligands binding transferrin, insulin, and low-density lipoprotein receptors (LDLR) have been especially appealing because of their transcytotic properties. LDLR, in particular, are of additional interest as they are overexpressed in several human conditions including lung, stomach, and cervical cancers. Several LDRL protein ligands, namely ApoB (Spencer and Verma 2007) ; ApoE (Re et al. 2011; Wagner et al. 2012) ; and Apo A-I (Fioravanti et al. 2012; Kratzer et al. 2007) , have been already used to functionalize diverse types of drugs and nanoparticles to allow or enhance BBB crossing. Others, such as Kunitz-derived peptides (Angiopeps), presented in plain protein-drug complexes, have entered clinical trials addressed to brain tumors (Kurzrock et al. 2012 ). (http://clinicaltrials.gov/ct2/show/ NCT01480583?term=ANG1005&rank=6). Although several of these LDLR ligands have proved to be promising, the ideal architecture for the drug-ligand complex to effectively cross the BBB and reach the brain remains to be elucidated. In particular, whether the ligand would be more effective when functionalizing a nanostructured vehicle than when applied in plain ligand-drug complexes remains unsolved, being a critical issue that needs further investigation (Juillerat-Jeanneret 2008) .
In the present study, we have selected several peptidic LDLR ligands and explored them as BBB crossers as well as architectonic tags, in protein-only materials with alternative presentations, namely unassembled protein species or protein-only regular nanoparticles. The in vitro and in vivo analyses of cell penetrability, biodistribution, and brain targeting provide new concepts about the BBB-crossing properties of functional protein nanoparticles, and suggest divergent diffusion properties of BBB-targeted nanoparticles when acting in cell culture and upon systemic administration.
Materials and methods

Protein production and purification
Vectors derived from pET-22b and harboring angiopep-2-GFP-H6, seq-1-GFP-H6, and apoB-GFP-H6 gene sequences had been designed in-house and constructed by Genscript. These plasmids were transformed into Escherichia coli BL21 (DE3) and positive clones selected in the presence of 100 lg/ml ampicillin. Transformed bacteria were cultured in 750 ml LB (Luria-Bertani, Conda Cat. 1551.00) medium in the presence of 100 lg/ml ampicillin at 37°C until OD 550 = 0.5, and incubated further overnight at 28°C with 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) to trigger protein production. Bacteria were harvested through centrifugation and resuspended in Tris buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM Imidazol) in the presence of EDTA-free protease inhibitor (Complete EDTA-Free; Roche).Then, cells were disrupted by a French press (Thermo FA-078A) at 1100 w, and the soluble fraction separated from the mixture by centrifugation at 15,0009g for 30 min. The insoluble fraction from ApoB-GFP-H6 was stored at -80°C for further use.
All proteins were purified by His affinity chromatography in an Ä KTA purifier FPLC (GE healthcare). After filtering the soluble fraction, samples were loaded onto HiTrap Chelating HP 1 ml columns (GE healthcare), washed with Tris wash buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, and 10 mM Imidazol) and eluted in a lineal gradient with Tris elution buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, and 500 mM Imidazol). After purification, corresponding fractions were collected and then dialyzed against carbonate buffer (166 mM NaHCO 3 , pH 7.4) overnight at 4°C. Proteins were characterized by mass spectrometry and quantified by Bradford assay. Some of these activities were technically supported by the Protein Production Platform CIBER-BBN/UAB (http://www.ciber-bbn.es/en/programas/89-plataformade-produccion-de-proteinas-ppp).
Protein purification from inclusion bodies
The pellet of ApoB-GFP-H6 IBs was washed with water twice, and resuspended with solubilizing buffer (40 mM Tris with 0.2 % N-lauroyl sarcosine, pH 8.0) in a ratio 1:40 and incubated for 24 h at room temperature. After that, the sample was centrifuged at 15,0009g for 30 min. Resuspended soluble protein from IBs was purified as described above with prior Nlauroyl sarcosine removal using a Hitrap QFF ion exchange column (GE healthcare).
Cell culture and flow cytometry HeLa (ATCC-CCL-2) cells were cultured in DMEM (GIBCO, Rockville, MD) supplemented with 10 % Fetal Calf Serum (GIBCO) at 37°C and 5 % CO 2 . Human umbilical vein endothelial cells (HUVEC) were maintained in M199 (Invitrogen) with 5 % Fetal Calf Serum (FBS) and 1.2 mM L-glutamine, at 37°C. Cells were incubated with recombinant proteins (1 and 9 lM) for 24 h and further treated with 1 mg/ml trypsin for 15 min to remove non-internalized protein.
Then, cells were collected and analyzed on a FACSCanto system (Becton-Dickinson), using a 15 W air-cooled argon-ion laser at 488 nm excitation. GFP fluorescence emission was measured with detector D (530/30 nm band pass filter). In endosomal escape of proteins experiment, chloroquine was added 1 h before adding protein to the cell, and reach a final concentration of 100 lM, after that, cells were incubated with chloroquine and recombinant protein for 24 h, and then treated with the same procedure. For the inhibition assay, HeLa cells cultured in serum-free medium for 24 h (80 % confluence) were exposed to ApoB-GFP-H6IBs (9 lM) protein and simultaneously to increasing concentrations of suramin. After incubation for further 24 h, intracellular fluorescence was determined as described above.
Transmission electron microscopy (TEM)
Purified proteins were diluted to 0.2 mg/ml in dialysis buffer (166 mM NaHCO 3 , pH 7.4), deposited onto carbon-coated grids for 2 min, stained with uranyl acetate, and observed in a Hitachi H-7000 transmission electron microscope.
Confocal microscopy
HeLa cells were seeded on Mat-Teck culture dishes (Mat Teck Corp., Ashland, MA, USA), and after 24 h, 2 lM of protein was added to cell culture, then it was incubated for another 24 h. The nucleus was stained with Hoechst 33342 (0.2 lg/ml, Molecular Probes) and plasma membrane was stained with CellMask TM Deep Red (2.5 lg/ml, Molecular Probes) for 5 min in darkness. Later, cells were washed with PBS (SigmaAldrich Chemie GmbH, Steinheim, Germany). Stained cells were examined using TCS-SP5 confocal laser scanning microscope (Leica Microsystems, Heidelberg, Germany) with a Plan Apo 639/1.4 (oil HC 9 PL APO l blue) objective. Hoechst 33342 was excited by a blue diode (405 nm) and detected at the 415-460 nm range. GFP proteins were excited by an Ar laser (488 nm) and detected at the 525-545 nm range. CellMask was excited by a HeNe laser (633 nm) and detected at the 650-775 nm range. Z series were collected at 0.5 lm intervals.
Fluorescence determination and dynamic light scattering (DLS)
All proteins were diluted to 400 lg/ml; then GFP fluorescence was determined by Cary Eclipse Fluorescence Spectrophotometer (Variant) at detection wavelength of 510 nm, by using an excitation wavelength of 450 nm. Volume size distribution of nanoparticles and monomeric GFP fusions were determined by dynamic light scattering at 633 nm (Zetasizer Nano ZS, Malvern Instruments Limited, Malvern, UK).
Cell permeability analysis
Permeability studies were performed at the USEF Drug Screening Platform (http://www.usc.es/en/ investigacion/riaidt/usef). Briefly, CaCo2 cells were cultured in DMEM high in glucose supplemented with 10 % FBS, 1 % non-essential amino acids (1009), 1 % L-glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin, 95 % air, and 5 % CO 2 and at 37°C. The cells (CaCo2, passage 65) were seeded in the apical compartment of a sterile 6-well transwell at a density of 250,000 cells/well in 1.5 ml of medium, and 2.5 ml of fresh medium was then added to the basal compartment. Cells were maintained in this medium for 21 days until complete differentiation (renewing the medium every 2 days). After this time, the medium was changed to HBSS (0.9 mM CaCl 2 , 0.5 mM MgCl 2 , and 20 mM HEPES, pH 7.4).
Transepithelial resistance (TEER) measurement was conducted using a Millipore epithelial voltmeter (Millicell-ERS) in a 6-well transwell (Costar). After adding HBSS in both compartments, samples were added in the apical part at different time intervals (0, 30, 60 s, and 20 min) for TEER measurements. To determine protein transport through Caco2, the amount of transported protein was determined by the measurements of fluorescence in basal compartment over time. Experiments were performed in triplicate. Data were expressed as % of initial TEER. The % is calculated based on the formula: % Initial TEER = (TO/ TI) 9 100, where TO is the TEER observed in the wells with the samples under study and TI is the TEER observed before the addition of samples. The transport was assessed by the apparent permeability (cm/sec), the amount is represented as protein against time, and the slope of the linear fit (D amount/D time) was used to calculate the apparent permeability (Papp) by the formula: Papp = (D amount/D time)/(A 9 C 0 ), where A is the area of the growth surface (4.71 cm 2 ) and C 0 is the initial concentration (lM) present in the apical compartment.
In vivo model and biodistribution analyses
Five-week-old female Swiss nu/nu mice weighing between 18 and 20 g (Charles River, L-Arbresle, France) and maintained in SPF conditions were used for in vivo studies. All the in vivo procedures were approved by the Hospital de Sant Pau Animal Ethics Committee and performed according to EC directives. Proteins were injected intravenously at a dose of 500 lg/mouse (n = 3 mice), control mice was injected with NaHCO 3 buffer. At 30 min and 2 h after injection, mice were sacrificed, and brain, kidney, lung, and liver were collected and examined separately for GFP fluorescence in an IVIS Spectrum equipment (Xenogen, France). The ex vivo fluorescent recording of the brain was performed sequentially, first measuring the emission from whole brain and then of sagittal sections to achieve a complete fluorescent signal characterization.
Statistical analyses
Data were analyzed using one-way ANOVA and post hoc Tukey tests.
Results
Three chimerical genes were constructed to produce LDLR-binding recombinant proteins (Table 1) , based on the following modular organization; from N-to C-termini, ligand, linker, EGFP, and H6 tail (Fig. 1a) . Such organization had been previously proved useful in promoting the spontaneous formation of highly stable fluorescent protein nanoparticles, provided a sufficient positive electrostatic charge is present at the N-terminus of the whole fusion (Céspedes et al. 2014; Unzueta et al. 2012a, b) . The ligands selected here were also tested for their ability to promote the assembling of the modular protein into nanoparticles. Angiopep-2 and Seq-1 fusions were produced in E. coli as fully soluble versions, while ApoB-GFP-H6 obtained from the soluble cell fraction was partially proteolized. In fact, protein sequencing by Edman degradation procedure of the soluble protein forms revealed loss of the amino-terminal 34-mer peptide of ApoB (Table 1) in approximately 50 % of the protein population (not shown). Then, since the LDLR ligand was lost in this protein fraction, the concentration of this construct was adjusted in further experiments to manage a comparative amount of fulllength protein. However, in the insoluble cell fraction, the full length ApoB-GFP-H6 was detected as a unique protein band (Fig. 1b) . Mass spectrometry analysis demonstrated that the insoluble protein version showed the predicted molecular mass corresponding to the intact construct. In vitro refolding of ApoB-GFP-H6 IBs rendered homogeneous soluble protein preparations.
In a preliminary screening (Unzueta et al. 2012a, b) , Angiopep-2 and Seq-1 were observed as unable to promote the assembling of the fusion proteins in higher order nanoparticles, probably due to their low cationic amino acid content, although doubts remained about the potential influence of the composition of the different buffers used to store the proteins. All the proteins produced here were tested again for nanoparticle formation under homogeneous buffer conditions as described above, in 166 mM NaHCO 3 , pH 7.4. The exclusive occurrence of unassembled forms of Seq-1-GFP-H6 and Angiopep-2-GFP-H6 was indeed confirmed (Fig. 2a) , with a particle size, determined by DLS, compatible with that of GFP monomers or dimers (as GFP naturally tends to dimerization). Contrarily, ApoB-GFP-H6 formed nanoparticles in both its natural soluble form directly obtained from recombinant bacteria (ApoB-GFP-H6s), or when refolded in vitro from IBs (ApoB-GFP-H6IBs) (Fig. 2a) . However, ApoB-GFP-H6s nanoparticles appeared to be unstable, as they peaked at 28 nm but also over 100 nm, indicative of aggregation. ApoB-GFP-H6IBs nanoparticles, instead, showed a unique monodisperse peak at 18 nm (Fig. 2a) , compatible with the formation of robust supramolecular structures. The aggregation of ApoB-GFP-H6s suspected in DLS measures was clearly confirmed by TEM, since amorphous protein clusters abounded in the fields (Fig. 2b) . This was in contrast with the highly regular architecture observed in 18 nm-ApoB-GFP-H6IBs Bold amino acid letter: first amino acid detected in the short ApoB form in the soluble cell fraction VLDLR very-low-density lipoprotein receptor, N/A not available but a LDLR family member, LDLR low-density lipoprotein receptor particles (Fig. 2b) . Interestingly, all recombinant proteins retained GFP fluorescence (Fig. 2c) , with only moderate reduction in the case of Angiopep-2-GFP-H6 and ApoB-GFP-H6IBs. Importantly, the preservation of fluorescence emission allowed further characterization of the constructs' biological properties by fluorescence analysis and imaging. In this regard, we first wanted to explore cell penetrability of all constructs in cells displaying and not displaying LDLRs. Uptake of protein constructs in LDLR -HUVEC was indeed negligible when comparing with that of closely related nanoparticles empowered by the unspecific but highly efficient cell penetrating peptide R9 [nine sequential arginines, (Vazquez et al. 2010 )] (Fig. 3a) . In contrast, penetrability was clearly higher in LDLR ? HeLa cells (Fig. 3b) , especially in the case of ApoB-GFPH6IBs. Although these data already suggested specificity in cell binding and penetration, the LDLRdependence in the uptake of these particles was further explored using the antibiotic suramin (a symmetrical polysulfonated naphthylamine derivative of urea), a potent inhibitor of LDL-LDLR interactions (Schneider et al. 1982; Nikanjam et al. 2007; Martins et al. 2000) , in the internalization assays. As expected, this drug dramatically inhibits the entrance ApoB-GFPH6IBs into HeLa cells (Fig. 4) , thus fully confirming the specific route by which the protein interacts and penetrates cells. In the presence of chloroquine, internalization of ApoB-GFP-H6IBs protein in HeLa cell population dramatically increased (Fig. 5) , indicative of an endosomal route as expected for any receptor-mediated uptake (Vazquez et al. 2008) . Interestingly, the penetrability of ApoB-GFP-H6s was always lower than that of ApoB-GFP-H6IBs. This fact suggests that an unstable nanoparticle might be less suitable for proper receptor binding and cell internalization. Alternatively, the folding status of the protein (probably different as derived from the soluble cell fraction or from refolding) might influence ligand exposure and/or particle performance in a biologically significant way. The efficient cell penetration of ApoB-GFP-H6IBs was fully confirmed by confocal microscopy (Fig. 6) . In general, the unassembled constructs were internalized by cells in a less efficient way, and the uptake was not influenced by background protein precipitation in the extracellular medium that has been generally observed in GFP-based selfassembling proteins (Vazquez et al. 2010) .
Considering these cell internalization results, the transepithelial crossing efficiency of the LDLR-ligand functionalized modular proteins was determined in a validated in vitro BBB model based on CaCo2 cells (Hellinger et al. 2012) , and the results are presented in Table 2 . In the two protein concentrations tested, ApoB-GFP-H6IBs presented the highest penetrability in accordance with the internalization assays presented above (Fig. 3) . Angiopep-2-GFP-H6 and Seq-1- GFP-H6 also displayed minor but still important penetrability in this BBB model at high protein concentration, thus suggesting a potential to effectively cross the BBB. However, when ApoB-GFP-H6s was challenged to the CaCo2 cell barrier, the apparent permeability was even lower than the negative control GFP, again indicating a failure of these protein nanoparticles to reach a fully functional status. Indeed, the integrity of the CaCo2 monolayer is maintained throughout the experiment since the Papp data of ApoB-GFP-H6s remains low at the two tested protein concentrations.
In a step further, and particularly encouraged by the good performance of ApoB-GFP-H6IBs nanoparticles, we wanted to examine the biodistribution of the protein set and the potential influence of the supramolecular protein organization, upon systemic administration through the tail vein in healthy mice in which side events that affect brain permeability such as enhanced permeability and retention (EPR) effect do not take place. We were specifically interested in this issue as at one side, LDLR are important targets in BBB crossing for drug delivery into the CNS (Demeule et al. 2008; Kim et al. 2007; Spencer and Verma 2007) , and also, cationic protein nanoparticles are biocompatible materials that fulfill most of the requests posed for vehicle-mediated drug delivery into brain (Juillerat-Jeanneret 2008) . Therefore, we analyzed ex vivo the signal from the whole brain to avoid the noise coming from the background Proteins were added to the cultures at two alterative concentrations, namely 1 and 9 lM. Those proteins showing significant differences with GFP-H6 are labeled with asterisks (**p \ 0.01; *p \ 0.05) of the whole body imaging followed by ex vivo recording of brain sagittal sections to complete evaluation of the extent of the emitted fluorescence. The analyses of these samples clearly indicated BBB-crossing properties of Angiopep-2-GFP-H6 and Seq-1-GFP-H6 (Fig. 7a) . Angiopep-2-GFP-H6, in particular, was observed as accumulating in the brain parenchyma 30 min after administration, a fact that was fully assessed by quantitative analysis of fluorescence under conditions that not allowed GFP-H6 background signal (Fig. 7b, c) . Surprisingly, not only ApoB-GFP-H6s but also ApoB-GFP-H6IBs failed to accumulate into brain (Fig. 7) , indicating that the ApoB ligand, in form of nanoparticles, was unable to promote BBB crossing.
To understand better the stability in circulation and the potential renal clearance of BBB crossing and failing construct variants, GFP fluorescence was also determined in kidney. All the constructs that did not form nanoparticles (namely Angiopep-2-GFP-H6, Seq-1-GFP-H6, and the parental GFP-H6) and also the unstable ApoB-GFP-H6s nanoparticles accumulated in kidney (Fig. 8a, b) . This observation strongly suggests renal clearance as it was in agreement with the hydrodynamic size of these materials being under 8 nm, the cut-off for renal filtration (Céspedes et al. 2014 ). This corresponds to the inability of Angiopep-2-GFP-H6 and Seq-1-GFP-H6 to self-assemble, and it also suggests that the ApoB-GFP-H6s nanoparticles, observed in vitro as unstable, probably disassemble once in the bloodstream (maybe due to the high salt content of the biological fluid). No fluorescence was recorded in lung and liver, in any case (not shown). The renal clearance is expected to dramatically reduce circulation time, what would prevent ligand-containing proteins from reaching their target (or at least, it would largely reduce the opportunities for interaction). This is exemplified by the incapability of a monomeric, T22-empowered IRFP protein to reach CXCR4 ? tumoral cells in a colorectal cancer model at detectable levels, being this protein found, instead, in kidney (Céspedes et al. 2014) . Contrarily, the assembled version of the same protein accumulated intracellularly in tumor but not in kidney (Céspedes et al. 2014) .
These data indicate that a nanoparticulate architecture of ligand-containing proteins, promoting efficient cell penetrability and transcytosis, is neither sufficient nor necessary to reach the brain under systemic administration, and that unassembled soluble proteins, even when undergoing an effective renal clearance, are able to cross the BBB in a significant fraction.
Discussion
Proteins are excellent functional carriers for therapeutic nucleic acids and conventional drugs (Aris and Villaverde 2004; Nehate et al. 2014) . When fused to the amino terminus of a His-tagged GFP, the cationic peptide ApoB promotes the formation of nanoparticles that are only composed by the modular protein acting Fig. 4 Specificity in the internalization of protein nanoparticles. Suramin-mediated inhibition of ApoB-GFP-H6IBs (protein concentration at 9 lM, and Suramin concentration at 1, 5, and 10 mM, respectively) penetration in HeLa cells was determined by both total fluorescence emission (a) and by the fraction of fluorescent cells (b). Significant differences in the uptake in the presence of the inhibitor relative to the protein alone are labeled with asterisks (*p \ 0.05) as self-interacting building block. This is based on a recently proposed protein engineering approach that allows designing protein nanoparticles by the fusion of cationic peptides to polyhistidine-tagged polypeptides. The directed formation of protein-only nanoparticles acts irrespective of the nature and sequence of the core protein, since the assembling of several unrelated proteins has been achieved by taking this architectonic principle (Céspedes et al. 2014; Unzueta et al. 2012a, b) . Nanoparticle formation is promoted by the electrostatic contacts between the resulting dipolar monomers, but the whole supramolecular structure is largely stabilized by additional forces such as Van der Waals, hydrogen bond interactions (Céspedes et al. 2014; Unzueta et al. 2014) , and protein-DNA interactions if used as non-viral gene therapy vehicle . Interestingly, the amino-terminal cationic peptide (ApoB in case of the current study) acts as an architectonic tag but also as a LDLR ligand with known BBB-crossing properties (see Table 1 ). Under the same conditions, the less cationic Seq-1 and Angiopep-2 peptides, also LDLR ligands, fail in promoting nanoparticle formation (Fig. 2) .
On the other hand, ApoB-GFP-H6 nanoparticles have been obtained from two alternative protein sources, namely the soluble E. coli cell fraction (ApoB-GFP-H6s) or by in vitro refolding of purified ApoB-GFP-H6 IBs (ApoB-GFP-H6IBs). Although both protein versions act as self-organizing building blocks (Fig. 2) , ApoB-GFP-H6s nanoparticles are poorly stable as determined by DLS and by TEM (Fig. 2) . Then, the protein was found in kidney soon upon administration (Fig. 8) . Renal clearance was also observed in the parental GFP-H6 and in the unassembled Seq-1-GFP-H6 and Angiopep-2-GFP-H6 (Fig. 8) . In contrast, the robust ApoB-GFP-H6IBs particles with a regular size of 18 nm were not cleared by kidney, which might enable the construct for a more prolonged and stable circulation in the bloodstream. The time-extended occurrence of ApoB-GFPH6s in kidney 2 h after administration, not observed in any strictly monomeric protein (namely GFP-H6, Seg-1-GFP-H6, and Angiopep-2-GFP-H6, Fig. 8 ), could be indicative of a progressive disassembling of the nanoparticles once in the bloodstream, and of a dynamic balance between assembled and disassembled forms. This would favor the hypothesis of ApoB- GFP-H6s particles being less stable than other related constructs, which like T22-GFP-H6, maintain the multimeric structure in vivo, and completely escape from renal filtration (Céspedes et al. 2014 ). The differences in the stability of ApoB-GFP-H6IBs and ApoB-GFP-H6s, and also the differential cell penetrability of these constructs (Figs. 3b, 5 ), can be only attributed to different conformations of the protein as resulting from either the soluble cell fraction or from refolding from protein aggregates. For instance, the ApoB tail in ApoB-GFP-H6s might be more involved in cross-molecular contacts between building blocks and less available for cellular interactions. Of course, the heterogeneity in protein bands detected in the Western blot analysis of the soluble E. coli cell fraction, probably resulting from selective proteolysis (Fig. 1b) , could also contribute to this fact. Therefore, the conformational and structural status of protein building blocks of de novo designed nanoparticles, and the influence of the cell factory in the quality and properties of the final supramolecular assemblies are a currently neglected field that deserves deeper exploration . This is especially relevant in the context of emerging biomaterials resulting from in vivo fabrication , the rising number of conventional and non-conventional cell factories for protein and polymer production , and the new bio-engineering strategies to improve microbial biosynthesis regarding industrial and biopharma applications (Chen 2012; Mahalik et al. 2014; Rodriguez-Carmona and Villaverde 2010) . On the other hand, ApoB-GFP-H6IBs nanoparticles internalized cultured cells more efficiently than ApoB-GFP-H6s nanoparticle versions, and also than Seq-1-GFP-H6 and Angiopep-2-GFP-H6 proteins (Figs. 3b,  6 ). The penetration of ApoB-GFP-H6IBs took place, as expected, in LDLR ? cells but not in LDLR -cells (Fig. 3a) , and it is LDLR-dependent as it was blocked by the inhibitor dug suramin (Fig. 4) . The control R9-GFP-H6 nanoparticles, which are empowered by a potent Tat-inspired unspecific cell penetrating peptide (R9), do not show any LDLR-linked preference in internalization (Fig. 3) . The LDLR-dependent internalization process (Fig. 4) is dramatically enhanced by chloroquine (Fig. 5) , indicative of an endosomal pathway. Under these conditions, ApoB-GFP-H6IBs but no other constructs was essentially found in all cells among the population exposed to the nanoparticle, even when applied at moderate doses (1 lM).
Although based on the good performance in in vitro experiments, ApoB-GFP-H6IBs particles were highly promising regarding BBB crossing, none of the ApoBderived protein version was found in the brain parenchyma up to 2 h after I. V. administration (Fig. 7) . Surprisingly, Seq-1-GFP-H6 and Angiopep-2-GFP-H6 proteins were detected in brain in ex vivo imaging, with an occurrence that peaked at around 30 min. BBB crossing of these two proteins occurred even with important renal uptake (Fig. 8) , while skipping renal clearance did not promoted, by itself, brain localization of ApoB-derivatives. The reason for the lack of correlation between kidney uptake and BBB crossing in vivo is not apparent. However, the unexpected complexity of these findings suggests two possible non-exclusive explanations: (1) the existence of differences in the capacity for transcytosis between epithelial kidney cells and brain endothelial cells, as previously described for a different receptor (Su and Stanley 1998) , and (2) the existence of differences in BBB transcytosis specificity among the different LDL family receptors (e.g., LDLR vs. VLDLR), as recently reported (Deane et al. 2008) .
Finally, being ApoB a well-known BBB-crossing peptide for soluble drugs (Kreuter et al. 2002) and also when linked to nanoparticles (Kim et al. 2007 ), failure in a proper activity when empowering protein nanoparticles for endothelial transcytosis in the brain might be due to inappropriate presentation of the ligand in these kind of constructs. In fact, due to its cationic nature, ApoB acts as both architectonic and targeting agent with limited solvent exposure when compared to ligands in monomeric proteins. Although such a dual activity is not by itself an obstacle for proper biodistribution of protein nanoparticles (as exemplified by the peptide T22 in similar GFP-based constructs) (Céspedes et al. 2014; Unzueta et al. 2012a, b) and also for ligand-mediated cell penetrability (Figs. 3, 4, 5) , the most complex biological barriers imposed by brain vessels might represent a tighter bottleneck to proper biodistribution.
Conclusions
The results presented here about the exploration of three recombinant protein-only LDLR ligands, presented in a total of four versions, reveal that high cellular penetrability in cultured cells does not guarantee efficient BBB crossing and brain targeting mediated by transcytosis-associated receptors. Interestingly, the protein versions that form nanoparticles do penetrate cultured cells more efficiently than unassembled constructs, while the contrary is true regarding in vivo BBB crossing. Such a divergent performance prompts to carefully evaluate the convenience of using nanoparticulate materials for BBBcrossing therapies, which even being highly efficient in cell culture might find in vivo bottlenecks essentially distinguishable from those encountered when targeting organs other than brain. In addition, our findings suggest possible differences in the transcytosis capacity between epithelial and endothelial cells and among the different LDL receptor family members.
